What You Should Know:
- Limbic, a London-based provider of clinical mental health AI technology raises $14M led by Khosla Ventures.
- The funding, which also includes participation from Gaingels and Illusian, will fuel Limbic's expansion into the US healthcare market.
Proven Success in the UK, Expanding to the US
Limbic's clinical AI platform has already positively impacted over 260,000 patients within the UK's National Health Service (NHS) Talking Therapies program. This technology
Read More
Artificial Intelligence in Healthcare | News, Analysis, Insights - HIT Consultant
Memora Health, Intermountain Partner on Personalized, AI-Powered Care
What You Should Know:
- Memora Health, a provider of intelligent care enablement platforms, and Intermountain Health, an integrated healthcare delivery system, today announced a multi-year partnership to implement innovative care delivery programs.
- The strategic integration aims to expand access to high-quality care for patients across Intermountain's enterprise, initially focusing on cancer care.
Revolutionizing Cancer Care with AI
The initial phase of the partnership will
Read More
Oracle-Backed Cancer Startup Project Ronin Shutters
What You Should Know:
- Project Ronin, a software startup focused on applying AI to improve cancer care, announced its closure, Bloomberg first reports.
- The company, co-founded by Oracle co-founder and chairman Larry Ellison, cited financial difficulties as the primary reason for the shutdown.
Project Ronin Background
Founded in 2018, Ronin aimed to develop solutions that could rapidly analyze and interpret data within electronic health records systems used by hospitals.
Read More
ArteraAI’s Prostate Test Earns Recognition in NCCN Guidelines for Prostate Cancer
What You Should Know:
- ArteraAI, a leader in artificial intelligence (AI)-powered cancer tests, today announced a significant achievement – the inclusion of their ArteraAI Prostate Test in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer.
- This marks a major milestone for ArteraAI, solidifying its position at the forefront of AI-driven oncology and personalized patient care.
A First for AI-powered Testing
The ArteraAI Prostate Test is the
Read More
Spectral AI Appoints Peter M. Carlson as CEO
What You Should Know:
- Spectral AI, Inc. (Nasdaq: MDAI), a leader in AI-powered wound care diagnostics, announced key leadership changes and positive financial outlooks today.
- Peter M. Carlson assumes the role of Chief Executive Officer (CEO) and joins the Board of Directors. Mr. Carlson boasts a proven track record of driving growth and financial success for multiple public companies, including experience in the wound care industry.
- Wensheng Fan, after nearly four years as CEO,
Read More
Elsevier Health Launches Generative AI Clinical Decision Support Tool
What You Should Know:
- Elsevier Health, a global leader in medical information and data analytics, announced the launch of ClinicalKey AI, the first and most advanced clinical decision support tool in the US to leverage generative artificial intelligence (AI).
- Elsevier Health partnered with OpenEvidence, a leader in AI for medicine, on developing ClinicalKey AI. Additionally, Cone Health and the University of New Mexico provided valuable insights during the development
Read More
Hippocratic AI Launches Beta Testing of First Generative AI for Healthcare
Azalea Health Unveils AI Strategy to Transform Healthcare Workflows
What You Should Know:
- Azalea Health, a provider of cloud-based healthcare IT solutions and services, today announced its innovative approach to leveraging artificial intelligence (AI) to revolutionize healthcare workflows.
- The AI strategy focuses on enhancing efficiency, accuracy, and personalization while prioritizing patient privacy and data security.
Azalea's AI Strategy
Azalea's AI strategy is designed to address specific pain points and improve workflows for healthcare
Read More
Absci Announces $75M Public Offering to Fuel AI Drug Creation
What You Should Know:
- Absci Corporation (Nasdaq: ABSI), a company utilizing generative AI for drug discovery, announced today an initial public offering (IPO) of $75 million in common stock.
- This IPO aims to support the advancement of Absci's internal drug development programs, further investment in their Integrated Drug Creation™ platform, and general corporate purposes.
Offering Details
Absci intends to offer $75M of common stock, with an option to sell an additional $11.25M
Read More
Belong.Life Launches Conversational AI Cancer Mentor
What You Should Know:
Belong.Life, a leading global provider of AI-powered patient education and support solutions, has unveiled the BelongAI Dave - Cancer Mentor app to bring the most advanced and comprehensive cancer support technology to patients and caregivers around the world.The new solution marks a significant step forward in personalized cancer support, by providing patients with a proactive and comprehensive conversational-AI solution for managing their journey
Read More
